Yuan James Pétermann

Rifampicin Pharmacokinetics and Clinical Outcomes in Tuberculosis Patients with Comorbidities: A Descriptive Longitudinal Analysis

BackgroundTuberculosis (TB) patients with comorbid may experience altered rifampicin pharmacokinetics (PK) particularly in sub-Saharan Africa, affecting treatment response. necessitates a use of therapeutic drug monitoring (TDM) as a tool to identify suboptimal level. We describe...